Abstract
Introduction : Vascular endothelial growth factor (VEGF) is an important mediator of pathological neovascularization and ocular vascular permeability. In phase I ROP, VEGF levels decrease due to hyperoxia but increase sharply in phase II ROP due to hypoxia, which triggers retinal neovascularization. Purpose : T o increase understanding of anti-VEGF injection therapy as a management for ROP in order to avoid serious complications such as blindness in children. R esult : T he use of intravitreal therapy targeting VEGF is increasingly in demand and has changed the way of view in treating vitreoretinal disease in children, especially in cases with severe posterior abnormalities , media opacity, and unstable systemic Compared with laser , anti-VEGF allows retinal vasculature to further vascularize toward the peripheral retina . Conclusion : Although it has many advantages, it is necessary to have a good understanding and continuous observation of systemic side effects and long-term neurodevelopment in children after anti-VEGF injection given that this action is a new therapy compared to others.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
